~ Unfluencer ~ Vocalist in "The Shadow Band" I come in peace ποΈππ¦ π΄ββ οΈπ³οΈβΆβ€οΈ
Multiverse
Joined March 2021
- Tweets69.6K
- Following3.8K
- Followers3.3K
- Likes214K
Pinned Tweet
My body - my temple.
It's sacred holy ground.
Any (any) trespassing is breaking divine natural law, law so high that no paper construct could ever come even close.
The same goes for everyone,
awaiting to be recognized and acknowledged
β€οΈ
Much love /t-one
ππ°π―π¦ retweeted
They're in different "information silos" than we are. They have no idea. π
ππ°π―π¦ retweeted
It's still loaded with plasmids (bacmids), moth DNA and transfection agents.
It doesn't work for COVID and it causes myocarditis.
It's not a win for anyone and Sweden retained their rights to procure mRNA updated vaccines.
ππ°π―π¦ retweeted
Why is anyone calling this progress or a βwin?β
Nuvaxovid is the brand name for the Novavax Cvd 19 π, (a protein subunit, adjuvanted). It is the same platform (originally developed by Novavax; later commercialized with Sanofi involvement in many markets through the Gates Foundation.
The antigen is a recombinant SARS-CoV-2 spike protein produced using a baculovirus expression system in Sf9 insect cells derived from the fall armyworm moth (Spodoptera frugiperda). The proteins are harvested, purified, and assembled into nanoparticles.
It is adjuvanted with Matrix-M, which contains saponin fractions (including material related to QS-21) extracted from the bark of the soapbark tree (Quillaja saponaria).
IgG4 is HIGHER in Novovax than any other COVID shot. Baculovirus (moths, bugs)
(Virus replicates and produces the spike, which are then harvested and mixed with QS21 (tree bark) and injected.)
Iβm sorry but anyone calling this progress or good news needs to do further research.
But hey, now they have an illusion of choice. Poison vs poison. Thatβs progress I guess.
Sweden opts for coronavirus protein vaccine instead of mRNA
From the 2027/2028 season onwards, Sweden will use only a protein-based coronavirus vaccine for its national vaccination campaign. It is the first country in the world to say goodbye to the mRNA vaccines.
Difference in technology
Nuvaxovid is a classic protein vaccine. It contains a ready-made piece of the virus (the spike protein), produced using recombinant technology (a molecular method in which DNA from different organisms is combined in the laboratory and placed into a host cell (such as a bacterium or yeast) to allow it to multiply or produce proteins) and provided with an adjuvant (an excipient that stimulates and strengthens the body's immune response to the antigen, so that the vaccine works better). The body is presented with this protein directly to build an immune response. This differs from mRNA vaccines (such as Comirnaty from Pfizer/BioNTech), where the body's cells must produce the spike protein themselves after receiving the mRNA instruction. This process carries the risk of autoimmune reactions, especially because these products do not remain at the injection site but can spread throughout the body. Furthermore, the quantity and duration of spike protein production are not defined in the mRNA technique. In addition, the lipid coating of the mRNA vaccines is very reactive. All in all, this leads to a disproportionate number of side effects, some very serious and resulting in death (1-3).
Sweden chose its own path during the coronavirus years by not enforcing lockdowns or school closures. Although there was much criticism of this at the time, the Swedish approach was later appreciated ( De Morgen, 25 December 2023 ).
With the decision to phase out coronavirus mRNA vaccines, Sweden appears set to play a pioneering role once again. The Doctors' Collective, together with European partners, has been advocating for the cessation of mRNA vaccinations for quite some time.
Sources: Sanofi press release (April 21, 2026), LΓ€kemedelsVΓ€rlden report and LΓ€kemedelsmarknaden report regarding the tender.
References
Cappelletti-Montano B, Demuru G, Laconi E and Musio M (2023) A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults. Front. Public Health 11:1145645. doi: 10.3389/fpubh.2023.1145645
Szebeni, J. Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges. Pharmaceutics 2025, 17, 450.
Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31. PMID: 36055877; PMCID: PMC9428332.
artsencollectief.nl/zweden-kβ¦
